Vol 14 (2023): Continuous Publishing
Review paper
Published online: 2024-04-17

open access

Page views 161
Article views/downloads 120
Get Citation

Connect on Social Media

Connect on Social Media

Bispecific antibodies in the treatment of follicular lymphoma

Aleksandra Bogucka-Fedorczuk1, Tomasz Wróbel1
Hematology in Clinical Practice 2023;14:80-86.

Abstract

Follicular lymphoma (FL) is the most common indolent non-Hodgkin lymphoma. The course of the disease is recurrent with varying periods of remission among individual patients. Treatment in the second and subsequent lines poses a therapeutic challenge, especially in patients with early disease recurrence. Using standard rituximab-based therapy, the progression-free survival (PFS) after the second line of treatment averages 10 months. Currently, new therapeutic options are being sought in this indication. One of the strategies under investigation in the FL treatment is chimeric antigen receptor T-cell therapy and bispecific antibodies. The second ones, by simultaneously binding to the CD3 antigen present on T-lymphocytes and CD20 on B lymphocytes, create an immunological synapse leading to neoplastic cell death. So far, after promising results of the clinical trials, the most extensively studied FL bispecific antibody, mosunetuzumab, has been registered for use in the third and further lines in relapsed and refractory FL. In the phase 2 study, the overall response rate was 80% and the median PFS was 17 months, despite the inclusion of patients with poor prognosis factors. Studies regarding the application of this drug in the first-line treatment are ongoing. Clinical trials have been also conducted with the use of antibodies such as epcoritamab and odronextamab. The aim of this work is an attempt to summarize the current knowledge regarding the effectiveness and safety of the investigated bispecific antibodies.

Article available in PDF format

View PDF Download PDF file

References

  1. Kanas G, Ge W, Quek RGW, et al. Epidemiology of diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) in the United States and Western Europe: population-level projections for 2020-2025. Leuk Lymphoma. 2022; 63(1): 54–63.
  2. Freedman A, Jacobsen E. Follicular lymphoma: 2020 update on diagnosis and management. Am J Hematol. 2020; 95(3): 316–327.
  3. Friedberg JW. Update on follicular lymphoma. Hematol Oncol. 2023; 41(Suppl 1): 43–47.
  4. Morschhauser F, Fowler NH, Feugier P, et al. RELEVANCE Trial Investigators. Rituximab plus lenalidomide in advanced untreated follicular lymphoma. N Engl J Med. 2018; 379(10): 934–947.
  5. Morschhauser F, Nastoupil L, Feugier P, et al. Six-year results from RELEVANCE: lenalidomide plus rituximab (R) versus rituximab-chemotherapy followed by rituximab maintenance in untreated advanced follicular lymphoma. J Clin Oncol. 2022; 40(28): 3239–3245.
  6. Batlevi CL, Sha F, Alperovich A, et al. Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups. Blood Cancer J. 2020; 10(7): 74.
  7. Casulo C, Dixon JG, Le-Rademacher J, et al. Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials. Blood. 2022; 139(11): 1684–1693.
  8. Maurer MJ, Bachy E, Ghesquières H, et al. Early event status informs subsequent outcome in newly diagnosed follicular lymphoma. Am J Hematol. 2016; 91(11): 1096–1101.
  9. Shouse G. Update on bi-specific monoclonal antibodies for blood cancers. Curr Opin Oncol. 2023; 35(5): 441–445.
  10. González Barca E. Role of bispecific antibodies in relapsed/refractory diffuse large B-cell lymphoma in the CART era. Front Immunol. 2022; 13: 909008.
  11. Budde LE, Sehn LH, Matasar M, et al. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. Lancet Oncol. 2022; 23(8): 1055–1065.
  12. Schuster SJ, Sehn L, Bartlett N, et al. Mosunetuzumab monotherapy continues to demonstrate durable responses in patients with relapsed and/or refractory follicular lymphoma after ≥2 prior therapies: 3-year follow-up from a pivotal phase II study. Blood. 2023; 142(Supplement 1): 603–603.
  13. Budde EL, Bartlett N, Giri P, et al. Subcutaneous mosunetuzumab is active with a manageable safety profile in patients (pts) with relapsed/refractory (R/R) b-cell non-hodgkin lymphomas (b-nhls): updated results from a phase I/II study. Blood. 2022; 140(Supplement 1): 3753–3755.
  14. McGough SF, Shamas N, Wang J, et al. Comparative effectiveness between mosunetuzumab monotherapy clinical trial and real-world data in relapsed/refractory follicular lymphoma in third or subsequent lines of systemic therapy. Leuk Lymphoma. 2023; 64(14): 2269–2278.
  15. Kang C. Mosunetuzumab: first approval. Drugs. 2022; 82(11): 1229–1234.
  16. Falchi L, Okwali M, Ghione P, et al. Subcutaneous (sc) mosunetuzumab (mosun) as first-line therapy for patients (pts) with high tumor-burden follicular lymphoma (FL): first results of a multicenter phase 2 study. Blood. 2023; 142(Supplement 1): 604–604.
  17. Hutchings M, Morschhauser F, Iacoboni G, et al. Glofitamab, a novel, bivalent cd20-targeting t-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory b-cell lymphoma: a phase i trial. J Clin Oncol. 2021; 39(18): 1959–1970.
  18. Shirley M. Glofitamab: first approval. Drugs. 2023; 83(10): 935–941.
  19. Bannerji R, Arnason JE, Advani RH, et al. Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Lancet Haematol. 2022; 9(5): e327–e339.
  20. Kim WS, Kim T, Cho SG, et al. Odronextamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): results from a prespecified analysis of the pivotal phase II study ELM-2. Blood. 2022; 140(Suppl 1): 1070–1071.
  21. Villasboas JC, Kim T, Taszner M, et al. Results of a second, prespecified analysis of the phase 2 study ELM-2 confirm high rates of durable complete response with odronextamab in patients with relapsed/refractory (R/R) follicular lymphoma (FL) with extended follow-up. Blood. 2023; 142(Suppl 1): 3041–3041.
  22. Hutchings M, Mous R, Clausen MR, et al. Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study. Lancet. 2021; 398(10306): 1157–1169.
  23. Linton K, Jurczak W, Lugtenburg P, et al. Epcoritamab SC monotherapy leads to deep and durable responses in patients with relapsed or refractory follicular lymphoma: first data disclosure from the epcore NHL-1 follicular lymphoma dose-expansion cohort. Blood. 2023; 142(Suppl 1): 1655–1655.
  24. Falchi L, Leppä S, Wahlin B, et al. Subcutaneous epcoritamab with rituximab + lenalidomide (r2) in patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL): update from phase 1/2 trial. J Clin Oncol. 2022; 40(16_Suppl): 7524–7524.
  25. Falchi L, Morschhauser F, Gribben J, et al. Phase 3 trial of subcutaneous epcoritamab in combination with rituximab and lenalidomide (R2) vs R2 among patients with relapsed or refractory follicular lymphoma (EPCORE FL-1). Blood. 2022; 140(Supplement 1): 9338–9339.
  26. Budde E, Gopal A, Kim W, et al. A phase 1 dose escalation study of Igm-2323, a novel anti-CD20 x anti-CD3 Igm T cell engager (TCE) in patients with advanced B-cell malignancies. Blood. 2021; 138(Supplement 1): 132–132.
  27. Mohty R, Kharfan-Dabaja MA. CAR T-cell therapy for follicular lymphoma and mantle cell lymphoma. Ther Adv Hematol. 2022; 13: 20406207221142133.
  28. Dreyling M, Fowler NH, Dickinson M, et al. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. Nat Med. 2022; 28(2): 325–332.
  29. Neelapu SS, Chavez JC, Sehgal A, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 2019; 20(1): 31–42.



Hematology in Clinical Practice